ICML 2023 | Early PET-adapted treatment for Hodgkin lymphoma: 10-year follow-up analysis

Massimo Federico, MD, University of Modena and Reggio Emilia, Modena, Italy, shares the results of a ten-year long-term follow-up analysis of the randomized intergroup EORTC/LYSA/FIL H10 trial (NCT00433433) which investigated the benefit of early PET (ePET)-adapted therapy following two cycles of standard ABVD chemotherapy for patients with Hodgkin lymphoma (HL). Prof. Federico shares the results for PET-negative and PET-positive patients with favorable (f) or unfavorable (u) HL. Following two cycles of ABVD, PET-negative patients received standard ABVD + radiotherapy, or ABVD only, and PET-positive patients received AVBD + radiotherapy or switched to BEACOPPesc + radiotherapy. The standard combination treatment was superior for PET-negative patients with fHL in terms of PFS, while no significant differences in PFS were seen for PET-negative patients with uHL and PET-positive patients in their respective experimental arms. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.